Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares [Yahoo! Finance]
Nuvectis Pharma, Inc. (NVCT)
Company Research
Source: Yahoo! Finance
NASDAQ:NVCT ) Director, Juan Sanchez, recently bought US$75k worth of stock, for US$5.79 per share. While we're hesitant to get too excited about a purchase of that size, we do note it increased their holding by a solid 20%. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Nuvectis Pharma Insider Transactions Over The Last Year In the last twelve months, the biggest single purchase by an insider was when insider Charles Mosseri-Marlio bought US$1.2m worth of shares at a price of US$5.00 per share. We do like to see buying, but this purchase was made at well below the current price of US$6.14. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive. While Nuvectis Pharma insiders bought shares during the last year, they didn't sell. The average buy price was around US$5.93. Although they bought at below the recent share price, it is good t
Show less
Read more
Impact Snapshot
Event Time:
NVCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCT alerts
High impacting Nuvectis Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
NVCT
News
- Nuvectis Pharma (NASDAQ:NVCT) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC [Yahoo! Finance]Yahoo! Finance
- Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLCGlobeNewswire
- CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewswire
- Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewswire
NVCT
Earnings
- 8/5/25 - Miss
NVCT
Analyst Actions
- 12/3/25 - HC Wainwright
NVCT
Sec Filings
- 11/6/25 - Form 4
- 11/6/25 - Form 4
- 11/6/25 - Form 4
- NVCT's page on the SEC website